-+ 0.00%
-+ 0.00%
-+ 0.00%

Chosa Oncology taps Bill Cronin to lead U.S. commercialization push for Platin-DRP

PUBT·07/10/2026 06:33:36
Listen to the news
Chosa Oncology taps Bill Cronin to lead U.S. commercialization push for Platin-DRP
  • Chosa Oncology appointed Bill Cronin to lead US business development, accelerating the planned commercialization of Platin-DRP in the US.
  • Cronin will be based in Kendall Square, Boston, expanding the group’s US presence as it builds a commercial organization.
  • Focus includes a planned Research Use Only launch of Platin-DRP, targeting partnerships across pharma, cancer centers, clinical labs.
  • Move follows SPLENDOUR study data showing 16.9-month median overall survival in predicted platinum responders vs 5.6 months in non-responders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.